Seroprevalence of Toxoplasma gondii and Neospora spp. Infections in Arab Horses, Southwest of Iran

Background: Because of the economic importance of the Arab race horses and also the role of Toxoplasma gondii and Neospora spp. in abortion and reproductive failure of these animals, we decided to perform this study. Objectives: We designed this study to investigate the seroprevalence of anti-Toxoplasma gondii and anti-Neospora spp. antibodies in Arab horses from 12 cities of Khuzestan province in southwest of Iran. Materials and Methods: From October 2009 to March 2011, a total of 235 blood samples were collected from jugular veins of Arab horses of different ages and genders from 12 cities of Khuzestan province. All the sera were tested for anti-Toxoplasma antibodies using the modified agglutination test (MAT) and the existence of anti-Neospora antibodies were tested using N-MAT for Neospora spp. Results: According to the MAT results, antibodies to T. gondii were found in 114 (48.5%) of 235 sera with titers of 1:20 in 84, 1:40 in 19, 1:80 in four, 1:160 in four, and 1:320 in three horses. According to the N-MAT results, antibodies to Neospora spp. were found in 47 (20%) of 235 sera with titers of 1:40 in 39, 1:80 in five, and 1:160 in three horses. We did not observe any statistically significant differences regarding age groups and genders between seropositive and seronegative horses for Neospora spp. using chi-square (chi(2)) test, but it seemed that anti-Toxoplasma antibodies were more prevalent in older horses ( >= 10 years old). Conclusions: The results indicated that Arab horses are exposed to these parasites in southwest of Iran. Further research is required to determine the genomic structures of these parasites in Arab horses in southwest of Iran

Transplacental transmission in cattle: is Toxoplasma gondii less potent than Neospora caninum?

We compared the transplacental-transmission ability of Toxoplasma gondii and Neospora caninum in cattle. One uninfected pregnant heifer served as control, while three were inoculated with N. caninum K9WA strain and four with T. gondii RH strain at their midgestational period. Both infected groups showed clinical signs and antibodies either to N. caninum or T. gondii, while the control animal was normal. Two (50%) Toxoplasma dams aborted on days 6 and 11 postinoculation. T. gondii tachyzoites were found in various organs of those dams that had abortions but not in their fetuses. Two Neospora dams did not abort but gave birth to subclinically infected calves. The remaining two Toxoplasma dams and one from Neospora group became recumbent. Those two dams and their fetuses showed disseminated Toxoplasma DNA, but no Neospora DNA was found. Our findings suggest that maternal toxoplasmosis could be a cause of abortion and congenital toxoplasmosis in cattle, especially when they are infected by virulent strains

Prevalence of Toxoplasma gondii indirect fluorescent antibodies in naturally- and experimentally-infected chickens (Gallus domesticus) in Thailand

Toxoplasma gondii infections in free-range (FR) chickens (Gallus domesticus) are potential public health risks. Antibodies for T. gondii were found in 194 out of 303 serum samples (64.03%) from FR chickens in Thailand tested by the indirect fluorescent antibody test (IFAT, 1:16). To verify the validity of serologic data in this survey, sera from chickens experimentally infected with the RH strain of T. gondii were tested by the IFAT. Antibodies against T. gondii were detected as early as 7 days p. i., peaked at 2 weeks, and then declined by 10 weeks p. i

A comprehensive review of Toxoplasma gondii biology and host-cell interaction: Challenges for a plant-based vaccine

Toxoplasmosisis a worldwide-distributed infection caused by Toxoplasma gondii, which causes a wide range of clinical syndromesin humans, mammals and birds. T. gondiiis considered a parasite of veterinary and medical importance, because it maycause abortion or congenital disease in its intermediate hosts. Despite theeconomic losses associated with T. gondiiinfection in farm animals and the socio-economic impact caused by this zoonoticdisease in the human population, there is no effective treatment available forhumans or animals able to eliminate the parasite from the host once the chronicinfection has been established. The only commercial vaccine is the S48 strainof attenuated tachyzoites for use in sheep. However, this vaccine causes sideeffects, has a short life time and induces a short-term immunity. So far, noacellular vaccine against toxoplasmosis has been commercialized. In fact, futurechallenges include the development of an effective vaccine to preventtoxoplasmosis. Most parasitologists and vaccinologists agree that futureefforts should be concentrated on developing multi-antigen vaccines and moreefficient delivery systems able to express heterologous proteins abundantly aswell as on searching for immunization schedules and adequate adjuvants toenhance the protective responses. To achieve this, platforms for the productionof acellular vaccines based on the use of plants can have an important role.Fil: Sander, Valeria Analía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús). Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús); ArgentinaFil: Ángel, Sergio Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús). Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús); ArgentinaFil: Clemente, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús). Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. Instituto de Investigaciones Biotecnológicas "Dr. Raúl Alfonsín" (sede Chascomús); Argentin